following a full submission
bivalirudin (Angiox) is accepted for restricted use within NHS Scotland.
Indication under review: as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. Bivalirudin should be administered with aspirin and clopidogrel.
Restriction: patients who would have been considered for treatment with heparin in combination with a glycoprotein IIb/IIIa inhibitor. It should not be used as an alternative to heparin alone.
In patients with STEMI undergoing PCI, bivalirudin, compared with heparin plus a glycoprotein IIb/IIIa inhibitor, was associated with significantly lower rates of major bleeding, cardiac death and thrombocytopenia.
Download detailed advice112KB (PDF)
Medicine details
- Medicine name:
- bivalirudin (Angiox)
- SMC ID:
- 638/10
- Indication:
- Anticoagulant in adult patients undergoing PCI, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.
- Pharmaceutical company
- The Medicines Company
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 September 2010